Johnson & Johnson (NYSE:JNJ) Shares Purchased by AE Wealth Management LLC

AE Wealth Management LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 416,357 shares of the company's stock after buying an additional 28,219 shares during the period. AE Wealth Management LLC's holdings in Johnson & Johnson were worth $69,049,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Norges Bank acquired a new stake in Johnson & Johnson in the fourth quarter valued at about $4,390,037,000. GAMMA Investing LLC lifted its position in Johnson & Johnson by 24,450.4% in the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after purchasing an additional 7,185,977 shares during the period. Bank of New York Mellon Corp lifted its position in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Janus Henderson Group PLC lifted its position in Johnson & Johnson by 134.5% in the fourth quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after purchasing an additional 4,559,147 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Johnson & Johnson by 12.3% during the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after acquiring an additional 3,363,235 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. UBS Group reiterated a "buy" rating and set a $190.00 price target (up from $180.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Guggenheim lifted their price target on shares of Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Bank of America lifted their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Trading Up 0.3%

JNJ traded up $0.52 during trading on Thursday, hitting $169.62. The company's stock had a trading volume of 6,629,361 shares, compared to its average volume of 8,401,730. The firm's 50 day moving average price is $155.75 and its 200-day moving average price is $155.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a market cap of $408.11 billion, a PE ratio of 18.14, a PEG ratio of 2.15 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the business earned $2.82 earnings per share. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.